Winner Medical Signs PurCotton Sales Agreement
Winner Medical to provide PurCotton raw materials, which will be processed into feminine products
Winner Medical has signed an agreement with a consumer products company in China, to provide PurCotton rolls. Under the agreement, Winner Medical will provide PurCotton raw materials, which will be processed into feminine products and then distributed throughout China by the consumer product company.
Jianquan Li, CEO, Winner Medical, said: We are delighted to announce the signing of the contract as it proved the recognition of top-tier clients to the premium quality of our PurCotton products.
This innovative, technologically-enhanced fabric offers significant advantages to synthetic nonwoven products, including eco-friendly, greater absorbency, and higher tensile strength. Furthermore, our patented advanced automation and design process reduces the average cycle time for production of the finished cloth from raw materials. We consider that this confirms the demand for PurCotton, and we believe PurCotton will give Winner Medical a strong competitive edge in the global marketplace, he added.
Related Insight
Suppliers Directory
Logopharm - Membrane Proteomics
LOGOPHARM GmbH provides specialised services in proteomic target and biomarker R&D with a strong focus on membrane proteins and antibodies.
Suppliers
QUMAS - Regulatory Compliance Solutions for the Pharmaceutical, Biotechnology and Medical Device Industries
Founded in 1994, QUMAS is an established leader in enterprise compliance management with proven success in deploying regulatory compliance solutions to over 250 global pharmaceutical, biotechnology and medical device companies.
Suppliers
Norwich Clinical Research Associates - Clinical Monitoring, Auditing, and Data Management Services
NCRA specializes in pre- and post-market studies for bringing investigational products to market and providing the necessary support once cleared / approved. NCRA is especially skilled in product development consulting, clinical monitoring, auditing, and data management services uniquely suited for the pharmaceutical, nutraceutical, medical device and biotech industries.
Suppliers
GCP-Service - Your Phase I-IV Clinical Trial Service Provider
With the national headquarters in Bremen (Germany), Michigan (USA) and Kaprijke (Belgium), GCP-Service is a 100% privately owned full-service Clinical Research Organisation (CRO). Since its foundation in 2004, the company has grown to a size that enables it to deliver all required services, while maintaining high flexibility and minimising overhead costs. This provides GCP-Service with the scope to conduct a wide variety of clinical studies, meeting the individual and specific needs of our clients. In 2010 GCP-Service has been ISO9001:2008 certified which reflects the excellent Quality System the company has in place.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Crystal Characterization of Almatis Tabular Alumina
Published by Phenom World
White Papers
Internet usage of Indian General Practitioners
Published by Kinapse
White Papers
Phenom™ use for pharmaceutical particle inspection
Published by Phenom World
White Papers
Reducing Analysis Limitations by Using Multiple Detectors with Ultra-Fast LC
Published by Shimadzu PBR
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.